Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Renal Cell Cancer

Presenters

Aude DESNOYER

Citation

Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

Authors

A. DESNOYER1, A. Larive2, D. Drubay2, E. Lanoy3, Y. Vano4, N. Rioux-Leclercq5, S. Chouaib6, B. Beuselinck7, F. Tantot8, B. Escudier9, N. Chaput10, L. Albiges11

Author affiliations

  • 1 Lio, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 2 Biostatistic And Epidemiology Unit, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 3 Biostatistic And Epidemiology Unit, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 4 Service D'oncologie Médicale, Hôpital Européen Georges Pompidou, 75015 - Paris/FR
  • 5 Service Anatomie Etcytologie Pathologiques, CHU, Université de Rennes, France, Rennes/FR
  • 6 Inserm U1186, Immunologie Intégrative Et Oncogénétique, Institut Gustave Roussy, Univ. Paris-Sud, Université Paris-Saclay, Villejuif/FR
  • 7 General Medical Oncology, University Hospitals Leuven, 3000 - Leuven/BE
  • 8 Getug Group, Unicancer, 75013 - PARIS/FR
  • 9 Department Of Oncology, Gustave Roussy Cancer Institute, 94805 - Villejuif/FR
  • 10 Laboratory Of Immunomonitoring In Oncology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 11 Medical Oncology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
More

Resources

Abstract 5105

Background

The NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with RCC in a “real world setting”. A translational research program was launched to characterize immune cell populations in fresh whole blood at baseline and after 2 months of treatment (C3) to determine association with high-grade toxicity and clinical outcome.

Methods

Absolute number of 106 immune cell populations were analysed in patients treated at a single institution as part of the NIVOREN GETUG-AFU 26 in fresh whole blood using dry formulation panels for multicolor flow cytometry. Predefined clinical endpoints were 6-month grade 3-4 toxicity (treatment related adverse event, TRAE) occurrence and 6-month disease progression occurrence. Missing values were imputed using multivariate imputation by chained equations. Multivariate differential count analysis was done using the DESeq2 R package.

Results

Overall 44 patients were included in this fresh whole blood immune-monitoring. Higher occurrence of grade 3-4 TRAE at 6 months was observed in patients with lower number of CD4+PD-1neg4.1BB+ T cell (non-exhausted activated CD4 T cells) counts at baseline (log2 fold change (LFC) = -1.993 95% confidence interval (95%CI)[-2.172; -1.815] ) and with lower number of CD56+ T cells (NKT cells) at C3 (LFC = -1.464 95%CI[-1.597; -1.331]). Higher occurrence of disease progression at 6-month was observed in patients with lower number of CD4+PD-1posCD69+ T cells (exhausted activated CD4 T cells) (LFC = -1.186 95%CI[ -1.308; -1.064 ]) and with higher number of CD4+CD244+ T cells (exhausted CD4 T cells) (LFC = 1.686 95%CI[ 1.533; 1.840]) at baseline. No immune cell populations were associated with the occurrence of a 6-month progression during the course of nivolumab (C3).

Conclusions

Fresh whole blood monitoring at baseline and after 2 months of nivolumab identified immune cell populations associated with grade 3-4 TRAE (CD4+PD-1neg4.1BB+ T cells and CD56+ T cells) and disease progression (CD4+PD-1posCD69+ T cells and CD4+CD244+ T cells). Functional analyses and external validation are ongoing.

Clinical trial identification

NCT03013335.

Editorial acknowledgement

Legal entity responsible for the study

UNICANCER.

Funding

Bristol-Myers Squibb.

Disclosure

B. Beuselinck: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): BMS. B. Escudier: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Ipsen; Advisory / Consultancy: EUSA; Advisory / Consultancy, Research grant / Funding (institution): Aveo. L. Albiges: Advisory / Consultancy, compensated to institution: Pfizer; Advisory / Consultancy, compensated to institution: Novartis; Advisory / Consultancy, compensated to institution: Roche; Advisory / Consultancy, compensated to institution: Bristol-Myers Squibb; Advisory / Consultancy, compensated to institution: IPSEN; Advisory / Consultancy, compensated to institution: MSD; Advisory / Consultancy, compensated to institution: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.